Two Sigma Advisers Reduces $5M in Allogene Therapeutics, Inc. ($ALLO)
Key Points
- Two Sigma Advisers changed its Allogene Therapeutics, Inc. ($ALLO) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $ALLO is Strong Buy and an average price target of $8.35.
- $ALLO last traded around $1.89.
Two Sigma Advisers reduced its position in Allogene Therapeutics, Inc. ($ALLO), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Allogene Therapeutics, Inc. after selling 2,890,200 shares during the quarter.
Allogene Therapeutics, Inc. ($ALLO) Stock
Allogene Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.